Luteolin Prevents Hyperoxaluria-Induced Renal Injury by Inhibiting Crystal Deposition and Renal Inflammation

Luteolin reduced calcium oxalate crystal deposition in mice and blocked PI3K/Akt signaling in kidney cells—no human data.

Journal: The International Journal of Biochemistry & Cell Biology | Published: 2026-02-09 | Type: Journal Article | PMID: 41672398 Authors: Jin Zhenghui, Zhu Shiqing, Wang Chengwei, Wang Tao, Liu Jihong, Wu Yue (Department of Urology, Tongji Hospital, Huazhong University of Science and Technology) Funding/COI: Funding not listed. Authors declare no competing interests.

Summary

Luteolin (LUT), a flavonoid found in plants like celery and parsley, was tested against calcium oxalate kidney stone formation using a stack of methods: database-driven network pharmacology, molecular docking, a mouse glyoxylate model, and cultured human kidney cells (HK-2). The study identified PI3K/Akt signaling—specifically the p85α regulatory subunit—as a candidate mechanism. In mice, LUT reduced visible crystal deposition and tissue damage; in cells, it blunted the inflammatory response to oxalate exposure.

Claims

• Network pharmacology identified 223 overlapping targets between luteolin and kidney stones across multiple databases
• Molecular docking gave a binding affinity of -6.947 kcal/mol between LUT and p85α, with complex stability confirmed through 25 ns molecular dynamics simulation
• In vivo: LUT "significantly reduced" renal CaOx crystal deposition and tissue injury in glyoxylate-treated mice (no quantified effect size reported in abstract)
• In vitro: LUT inhibited PI3K/Akt activation and reduced inflammatory cytokine production in HK-2 cells exposed to high oxalate
• CETSA (Cellular Thermal Shift Assay) offered indirect evidence that LUT physically engages p85α in cells

Study Quality

This is a preclinical study from start to finish. The methodological stack—network pharmacology → molecular docking → molecular dynamics → animal model → cell line—is standard for Chinese traditional medicine mechanistic papers, and that's a problem: each step is hypothesis-generating, not validating. Network pharmacology is essentially a bioinformatics exercise that identifies plausible targets from curated databases; 223 intersecting targets means the specificity is low. Molecular docking scores reflect computational binding geometry, not actual biochemistry. The mouse model is well-established for nephrolithiasis research, and CETSA is a legitimate target engagement assay, which is one of the more credible elements here.

No sample sizes, variance data, or specific p-values appear in the abstract. The quantitative results for the animal arm are described only qualitatively ("significantly reduced"), which makes independent assessment impossible from this summary alone. Funding is not disclosed, which is a gap.

Red Flags

• Zero human data — all findings are in mice or a single immortalized cell line (HK-2)
• Network pharmacology identifies 223 targets, then the paper focuses on one; the selection rationale is not explained in the abstract
• Effect sizes for the in vivo arm are not reported in the abstract — "significantly reduced" without numbers is not useful
• Molecular docking binding energy (-6.947 kcal/mol) is not strong compared to many approved drugs; the threshold for "strong" is contextual and not discussed
• Funding source undisclosed
• No comparison to standard-of-care treatments, positive controls with known efficacy, or dose-response data in the abstract
• "Prevention of nephrolithiasis" in the conclusion substantially outpaces what a mouse model can support

Strengths

• Multi-method approach adds cross-validation between computational and wet-lab findings
• CETSA for target engagement is more rigorous than docking alone
• Glyoxylate mouse model is a recognized standard for CaOx stone research
• Both in vivo and in vitro arms run in the same study, providing some mechanistic coherence
• No declared conflicts of interest from a team with no apparent industry ties

Verdict

A preclinical proof-of-concept with a plausible mechanism and a competent but conventional design. The PI3K/Akt angle is credible and the CETSA data elevates it above pure computational speculation. What this paper cannot do is tell you whether luteolin works in humans, at what dose, or whether it outperforms anything already in use. The absent effect-size numbers in the animal arm and the undisclosed funding are irritants. File under "interesting lead, a long way from the clinic."